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Negative Regulation of TLR Signaling by BCAP Requires
Dimerization of Its DBB Domain
Johannes U. Lauenstein,* Michael J. Scherm,* Atul Udgata,* Martin C. Moncrieffe,*
David I. Fisher,† and Nicholas J. Gay*
The B cell adaptor protein (BCAP) is a multimodular regulator of inflammatory signaling in diverse immune system cells. BCAP
couples TLR signaling to phosphoinositide metabolism and inhibits MyD88-directed signal transduction. BCAP is recruited to the
TLR signalosome forming multitypic interactions with theMAL andMyD88 signaling adaptors. In this study, we show that indirect
dimerization of BCAP TIR is required for negative regulation of TLR signaling. This regulation is mediated by a transcription
factor Ig (TIG/IPT) domain, a fold found in the NF-kB family of transcription factors. We have solved the crystal structure of the
BCAP TIG and find that it is most similar to that of early B cell factor 1 (EBF1). In both cases, the dimer is stabilized by a helix-
loop-helix motif at the C terminus and interactions between the b-sheets of the Ig domains. BCAP is exclusively localized in the
cytosol and is unable to bind DNA. Thus, the TIG domain is a promiscuous dimerization module that has been appropriated for a
range of regulatory functions in gene expression and signal transduction. The Journal of Immunology, 2020, 204: 2269–2276.
T
oll-like receptors are pattern recognition receptors that
respond to conserved microbial stimuli, such as LPS from
Gram-negative bacteria. These stimuli induce dimeriza-
tion of the receptor Toll/IL-1R (TIR) domains that act as a scaffold
for the recruitment of downstream signal transducers, leading to the
activation of NF-kB. Although receptor and adaptor TIR domains
are known to engage in homotypic and heterotypic interactions,
the stoichiometry and assembly of the TIR signalosome remains
unsolved. However, residues and interfaces in the TIR domains of
the TLRs, MyD88, and MAL adaptor proteins that are required for
signal transduction have been mapped (1–5). This has allowed a
range of structural models of the TLR signalosome to be proposed
based on dimeric adaptor proteins to match the stoichiometry of
activated receptor dimers (3, 4, 6, 7).
More-recent studies found that MyD88 andMAL have the ability
to form filaments in vitro, similar to other pattern recognition re-
ceptors such as NOD-like receptors (NLR), inflammasomes, and
antiviral RIG-I–like receptor (RLR) complex pathways (8, 9). This
filamentous model of higher-order oligomers of MyD88 death do-
mains, MyD88 TIR domains, and MAL TIR domains provides in-
sights into the various interaction interfaces required for signal
transduction. However, the physiological assembly and regulation
of these higher-order oligomeric structures remain to be determined.
An important regulator of TLR signaling is the B cell adaptor
protein (BCAP). BCAP is categorized as a negative regulator of
TLR signaling because BCAP-deficient macrophages produce
higher amounts of TLR-induced inflammatory cytokines IL-12,
IL-6, and TNF-⍺ (10). On a molecular level, BCAP links TLR
signaling to phosphoinositide metabolism through heterotypic TIR
domain interactions with MAL and MyD88 (11). The negative
regulation of TLR signaling depends on the recruitment and ac-
tivation of PI3K and phospholipase C-g2 (PLCg2), leading to
MAL degradation and endocytosis of TLRs (12, 13). Another
possible mechanism is that BCAP-mediated PI3K activation leads
to an increase in Foxhead box protein O1 (FoxO1) phosphoryla-
tion, resulting in nuclear export and reduced transcription of in-
flammatory genes (14).
The precise requirements and stoichiometry of TIR domain
interactions between BCAP, MAL, and MyD88 remain elusive.
Previous studies have shown that the Dof/BANK1/BCAP (DBB)
domain of BCAP is required for TIR domain interactions with
MAL and MyD88 as well as the negative regulation of TLR
signaling (11). The DBB domain is conserved in the Drosophila
protein Dof, the BCAP B cell scaffold protein with ankyrin repeats
(BANK1), and BCAP. The DBB domain, along with the ankyrin
repeat domain, has been suggested to drive dimerization of BCAP
(13, 15).
In this study we present a structural and functional analysis of the
BCAP DBB domain and its role in the TLR signalosome. We show
that the TIR domain of BCAP is sufficient for interaction withMAL
and that the DBB domain is essential for the negative regulation of
TLR signaling both in vivo and in vitro. Using a combination of
biophysical and structural techniques, we show that dimerization
of BCAP TIR by the DBB domain drives negative regulation of
TLR signaling. The structure of the BCAP DBB domain reveals
that it shares the same fold and dimerization interface as the
*Department of Biochemistry, University of Cambridge, Cambridge CB2 1GA,
United Kingdom; and †Discovery Biology, Discovery Sciences, R&D, AstraZeneca,
Cambridge CB4 0WG, United Kingdom
ORCIDs: 0000-0002-3289-9159 (M.J.S.); 0000-0002-2782-7169 (N.J.G.).
Received for publication October 7, 2019. Accepted for publication January 31,
2020.
This work was supported by a Wellcome Trust Investigator Award (to N.J.G.)
(WT100321/z/12/Z) and an AstraZeneca studentship (RG82667) (to J.U.L. and N.J.G.).
The structures presented in this article have been submitted to the Protein Data Bank
(http://www.rcsb.org) under accession number 6SWS.
Address correspondence and reprint requests to Prof. Nicholas J. Gay, Department of
Biochemistry, University of Cambridge, 80 Tennis Court Road, Cambridge CB2
1GA, U.K. E-mail address: njg11@cam.ac.uk
The online version of this article contains supplemental material.
Abbreviations used in this article: ATCC, American Type Culture Collection; BCAP,
B cell adaptor protein; DBB, Dof/BANK1/BCAP; HMGB1, high-mobility group B1
protein; IMAC, immobilized metal ion affinity chromatography; PDB, Protein Data
Bank; RMSD, root-mean-square deviation; SEC-MALS, size exclusion chromatog-
raphy combined with multiangle light scattering; SLE, systemic lupus erythematosus;
TEV, tobacco etch virus; TF, transcription factor; TIG, transcription factor Ig; TIR,
Toll/IL-1R.
This article is distributed under the terms of the CC BY 4.0 Unported license.
Copyright  2020 The Authors
www.jimmunol.org/cgi/doi/10.4049/jimmunol.1901210
transcription factor Ig (TIG) domains found in the NF-kB family of
transcription factors (TF). However, the BCAP TIG domain does
not bind to DNA.
Materials and Methods
Cell culture
THP-1 cells and Ramos B cells (RA 1; American Type Culture Collection
[ATCC]) were maintained in RPMI 1640 medium (supplemented with 10%
FBS, L-glutamine, 100 U/ml penicillin, and 100 mg/ml streptomycin; all
from Invitrogen). THP-1 cells were differentiated to macrophages using
10 ng/ml PMA (Sigma-Aldrich) for 12 h, followed by rest for 24 h in
complete RPMI 1640 medium. HEK293T cells (ATCC) were maintained
in DMEM (supplemented with 10% FBS, L-glutamine, 100 U/ml penicillin,
and 100 mg/ml streptomycin; all from Invitrogen). Expi293F cells (Thermo
Fisher Scientific) were cultured in Expi293 Medium (Life Technologies) at
140 rpm, 37˚C, and 8% CO2.
Cloning
Constructs for expression in mammalian cells used human BCAP in a
p3XFLAG-CMV-10 vector as a template to clone the BCAP TIR (1–145),
TIR-DBB (1–311), and TIR-DBB-ANK (1–426) domains into a pcDNA3.1–
3X-FLAG vector using KpnI and BamHI sites. Full-length BCAP (2–805)
was cloned into pcDNA3.1(+) with an N-terminal His-Avi-TEVcl-Tag using
HindIII and BamHI sites.
For bacterial expression, the TIG2a (179–288), TIR-TIG2a (7–288),
DBB-ANK (179–404), MBP-ANK (333–467), and MAL TIR domains
(79–221) containing a C-terminal Strep-tag were cloned into pMCSG7 or
pMCSG9 (DNASU) using ligation-independent cloning as described (16).
Immunoprecipitations
Various Myc and FLAG-tagged protein constructs were transiently trans-
fected into HEK293T cells (ATCC) using JetPEI (Polyplus Transfection
SA) according to the manufacturer’s recommendations. Twenty-four hours
posttransfection, cells were washed with 13 PBS and lysed using 300 ml
of Tris lysis buffer (20 mM Tris, 150 mM NaCl, 1 mM EDTA, 0.5%
Nonidet P-40, pH 8) supplemented with 13 protease inhibitor mixture
(Calbiochem). After 30 min of lysis at 4˚C with agitation, the mixture was
centrifuged at 16,0003 g for 10 min at 4˚C. The supernatant was collected
for immunoblotting or immunoprecipitation with EZview Red FLAG M2
beads (Sigma-Aldrich) according to the manufacturer’s recommendation.
For immunoblotting, Myc and FLAG-tagged proteins were visualized us-
ing anti-Myc (9E10; abcam) and anti-FLAG M2 (F3165; Sigma-Aldrich)
primary Abs, respectively. Anti-mouse-HRP IgG (A9044; Sigma-Aldrich)
was used as secondary Ab.
NF-kB reporter assay
HEK293T cells were seeded in a 96-well plate at 1.5 3 104 cells per well.
At 70–80% confluence, JetPEI (Polyplus Transfection SA) was used
according to the manufacturer’s instructions to transiently transfect cells
with the NF-kB reporter vectors pBIIX-luc and pCMV-Renilla-luc, and
cells were cotransfected as described with Myc-MAL, Myc-MyD88, and
FLAG-TIR, FLAG-TIR-DBB, FLAG-TIR-TIG2a, FLAG-TIR-DBB-ANK,
or FLAG-BCAP, totaling 100 ng of DNA per well in 100 ml of DMEM. At
24 h posttransfection, cells were washed in 13 PBS and subsequently lysed
in Passive Lysis buffer (Promega). The lysates were assayed for luciferase
activity using the Dual-Glo luciferase kit (Promega). Luciferase activity
shown is firefly luciferase relative to Renilla luciferase and normalized to
cells transfected with empty vectors.
Protein production for crystallography and
biophysical analysis
TIG2a and the DBB-ANK domain of human BCAP were expressed in
BL21(DE3) cells (Novagen) grown in Luria broth medium. After Ni-NTA
purification using immobilized metal ion affinity chromatography (IMAC)
buffer (50 mM Tris, 250 mM NaCl, 30 mM imidazole, 1 mM TCEP, pH
7.5) and elution in IMAC buffer containing 500 mM imidazole, samples
were treated with tobacco etch virus (TEV) protease to remove the hexa-
histidine tag. Further purification was performed using Superdex 200 (GE
Healthcare) size exclusion chromatography in 20 mM TRIS, 100 mM
NaCl, 1 mM TCEP (pH 7.5). The MAL TIR domain, MBP-ANK, and
GST-CRKL were expressed and purified as described above, but TEV
protease digestion was omitted.
For selenomethionine incorporation, the DBB domain was expressed in
BL21(DE3) cells grown in 1 l of M9 minimal medium supplemented with
0.05 g of selenomethionine, 0.1 g of lysine, 0.1 g of threonine, 0.1 g of
phenylalanine, 0.05 g of leucine, 0.05 g of isoleucine, and 0.05 g of valine.
Purification of selenomethionine-containing DBB domain was performed as
described for the unmodified protein.
For the expression of BCAP(FL), Expi293F cells were transiently
transfected with HisAviTEVclBCAP. At a density of 4 3 10
6 cells/ml,
6 mg/ml linear PEI Max (Polysciences) was used to transfect 1.5 mg/ml
plasmid DNA. Fresh medium was added to double the volume of the
culture 24 h after transfection. Cells were harvested 3 d posttransfection by
centrifugation. BCAP(FL) Ni-NTA purification was performed in high-salt
IMAC buffer (50 mM Tris, 250 mM NaCl, 30 mM imidazole, 1 mM TCEP,
pH 7.5) supplemented with 5 mM sodium orthovanadate, 50 mM sodium
fluoride, 60 mM b2glycerophosphate and protease inhibitor mixture
(Calbiochem). TEV protease digestion and size exclusion chromatography
were performed as described above.
Protein crystallization
Crystals were obtained using the sitting-drop vapor diffusion methods at
19˚C. The DBB-ANK domain crystallized at a concentration of 9 mg/ml
in 1.1 M malonate, 0.5% jeffamine ED-2003, 16% glycerol, and 0.1 M
HEPES pH 7.5. Crystals of native DBB were obtained at a concentration of
5.5 mg/ml in 1.3 M NaH2PO4, 0.7 M K2HPO4, and 0.1 M sodium acetate
(pH 4.5). The selenomethionine-containing DBB domain crystallized at
2.2 mg/ml in 0.9 M NaH2PO4, 0.9 M KH2PO4, and 0.1 M sodium acetate
(pH 4.5).
Crystallographic data collection and structure determination
DBB-ANK diffraction tests were conducted at the i02 beam-line (Diamond
Light Source, Oxford, U.K.). Native DBB diffraction data were collected at
ID30A-3 beam-line (European Synchrotron Radiation Facility, Grenoble,
France). The DBB single wavelength anomalous dispersion (SAD) dataset
was collected at Proxima 2A (Soleil, Saint-Aubin, France). Diffraction
data were indexed and scaled using XDS (17). Initial phases using the
anomalous signal from selenomethionine residues were obtained using
the Phaser SAD pipeline (18), and a partial model was obtained using
Buccaneer (19). Subsequent manual model building and refinement were
conducted using Coot (19) and Phenix (20) using a 3.1-A˚ native dataset.
The TIG2a structure has been deposited in the Protein Data Bank (PDB)
under accession number 6SWS (http://www.rcsb.org/).
Size exclusion chromatography combined with multiangle
light scattering
For size exclusion chromatography combined with multiangle light scattering
(SEC-MALS) analysis of DBB and DBB-ANK domains, 50-ml protein
samples at a concentration of 2 mg/ml were injected onto a Superdex 200
Increase 10/300 GL column (GE Healthcare). Differential refractometry
and multiangle light scattering data were collected using Optilab T-rEX
(Wyatt technology) and DAWN8+ (Wyatt technology) instruments, re-
spectively. Data analysis was performed using ASTRA (v6.1) software
(Wyatt technology).
Filament formation assay
Starting from a stock concentration of 10 mM, MAL and various BCAP
constructs were mixed at a molar ration of 1:10. The protein mixture was
then incubated at 30˚C for 1 h to induce filament formation of the MAL
TIR domain. Soluble and insoluble fractions were separated by centrifu-
gation at 16,0003 g for 10 min and subsequently analyzed by SDS-PAGE.
Immunofluorescence and image acquisition
Cells were fixed in 3.7% formaldehyde for 15 min and permeabilized with
0.1% Triton X-100 for 5 min. After blocking with 2%BSA in 13 PBS, cells
were immunostained with goat anti-BCAP (AF4857; R&D Systems) pri-
mary Ab and Alexa Fluor–conjugated secondary Ab (ab150129; Abcam).
Cells were mounted using Vectashield DAPI (Vector Shield) and visual-
ized using EVOS M5000 (LPlanFL PH2 203 objective; Invitrogen).
In vitro DNA pulldown
A total of 10 mg of purified BCAP(FL), DBB-ANK, GST-CRKL, or high-
mobility group B1 protein (HMGB1) (ab167718; Abcam) was applied to
20 mg of DNA cellulose (Merck) pre-equilibrated in 500 ml of binding
buffer (10 mM sodium phosphate, 100 mM NaCl, 1 mM DTT, 1 mM
EDTA, 10 mg/ml BSA, pH 7.5). Samples were then incubated for 1 h at
4˚C with shaking. Samples were applied to small gravity flow columns,
and the flowthrough was collected. The DNA cellulose was repeatedly
washed with 500 ml of binding buffer containing increasing amounts of
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NaCl to a final concentration of 600 mM. The resulting flowthrough was
subjected to a TCA precipitation, and samples were analyzed on SDS-PAGE.
Gel-retardation assay
Complementary 81-bp DNA strands were annealed at 95˚C for 5 min to
generate dsDNA. The duplex was diluted to 1 mM in binding buffer
(10 mM TRIS, 100 mM NaCl, 1 mM DTT, pH 7.5) and mixed with 10 mg
purified BCAP(FL), DBB-ANK, GST-CRKL, or HMGB1 (ab167718;
abcam). After 15 min at room temperature, the samples were diluted in
Hi-Density TBE sample buffer (Thermo Fisher Scientific) and ran on a 6%
acrylamide DNA retardation gel (Thermo Fisher Scientific). The acryl-
amide gel was prerun in 0.53 Novex TBE running buffer (Thermo Fisher
Scientific) at 100 V and 4˚C for 1 h, and the samples were run at the same
settings. The gels were fixed by washing in 35% ethanol and 5% acetone
for 5 min followed by SYBR safe (Thermo Fisher Scientific) staining to
visualize the DNA.
Results
The BCAP DBB domain is required for negative regulation of
TLR signaling
In previous studies, constructs containing both the TIR and DBB
domains were used to characterize BCAP as a negative regulator of
TLR signaling (11). To determine the role of the DBB domain in
the association with MAL and MyD88, HEK293T cells were
transiently transfected with FLAG-tagged BCAP constructs con-
taining varying domain boundaries (see Fig. 1F). Constructs
ranging from the TIR domain alone to full-length BCAP associate
with MAL (Fig. 1A). By contrast, association with MyD88 re-
quires the DBB as well as the TIR domain (Fig. 1B).
To further investigate the role of the DBB domain, we measured
the ability of BCAP truncations to inhibit signaling by MAL and
MyD88 in an NF-kB reporter assay. As expected, constructs
containing the TIR-DBB domains, TIR-DBB-ANK, or full-length
BCAP were able to inhibit NF-kB signaling induced by MAL and
MyD88 (Fig. 1C, 1D). The DBB domain was essential for this
regulation because the BCAP TIR domain alone was not able to
reduce NF-kB signaling for both MAL and MyD88 (Fig. 1C, 1D).
Interestingly, the TIR domain of BCAP enhances NF-kB pro-
duction (Fig. 1C, 1D). Given that the expression levels of MAL
and MyD88 were comparable (Fig. 1E) in all conditions, this
suggests that the BCAP TIR domain interacts differently with the
MAL and MyD88 TIR domain compared with longer constructs
containing the DBB and ANK domain or full-length BCAP. The
TIG2a construct is less effective at repressing signaling as com-
pared with TIR-DBB, TIR-DBB-ANK, and full-length BCAP.
This may be because, in the absence of the third a helix, dimer-
ization is less stable, consistent with our structural findings
(Fig. 2) (Fig. 3, Supplemental Fig. 1). Together, these results show
that the DBB domain is essential for negative regulation of TLR
signaling by BCAP.
DBB domain dimerization drives negative regulation of
TLR signaling
To understand the functional importance of the DBB domain, we
examined its oligomerization properties. A previous study has
shown that full-length BCAP is dimeric in solution (13). Further
studies using SEC-MALS show that a construct comprising the
DBB and ANK domains (residues 179–404) is also dimeric in
solution (Fig. 2A). By contrast, a DBB construct lacking the last
C-terminal a helix (TIG2a, residues 179–288, see Supplemental
Fig. 1) was monomeric in solution (Fig. 2A). These data imply
that the BCAP DBB domain functions as a dimerization domain
and that the dimer is stabilized by the third DBB a helix.
A recent study has shown that the MAL TIR domain assembles
into complex filaments in vitro and that some of the homotypic
interactions seen in the structure of these filaments are critical for
signal transduction (9). We therefore asked whether BCAP is able
to interfere with the formation of MAL filaments in vitro, as
assessed by differential centrifugation in which the MAL fila-
ments purify in the pellet fraction. As expected, MALTIR alone is
found in the pellet only, indicating the formation of large fila-
mentous structures. However, in the presence of full-length BCAP,
MAL TIR remains in the supernatant, suggesting that BCAP in-
hibits the TIR–TIR interactions that drive filament formation.
Neither the monomeric TIR-TIG2a nor the DBB-ANK constructs
affected formation of the MAL filaments (Fig. 2B). However,
BCAP and MAL did not form a stable complex under these
conditions, suggesting a transient nature of the filament disruption
(Fig. 2C).
The DBB domain structure has striking similarity to the NF-kB TF
family dimerization domains. To obtain structural information for
the DBB dimerization interface, a DBB-ANK construct was crys-
tallized. However, diffraction was limited to 7 A˚ and therefore in-
sufficient to obtain an atomic model. Subsequently, the shorter
TIG2a (Fig. 2A) construct was crystallized, and the structure was
solved at 3.1 A˚ using data from a native crystal and phases from a
selenomethionine derivative. Data collection, phasing, and refine-
ment statistics are summarized in Supplemental Table I. The DBB
domain structure reveals a typical TIG fold followed by two a
helices. The TIG domain is composed of seven b-strands (bA–bG)
that make up a C-type Ig fold with a broken bA strand (Fig. 3A).
The DBB TIG fold exhibits structural similarity to TIG domains
from several TFs despite low sequence similarity (Table I). It shares
an identical domain topology with the NFAT, NF-kB, CAMTA, and
Ebf1 TIG domains, with root-mean-square deviation (RMSD) val-
ues as low as 1.6 A˚ (21–24) (Fig. 3B). The NFAT5, p50 NF-kB, and
Ebf1 TIG domains are known to form functional dimers and assist
in DNA binding. The TIG dimerization interface in TF is composed
of symmetrical interactions of the ABED b-sheet. The conforma-
tion of these TF dimers shares a high level of similarity to one of the
crystal contacts in the TIG2a structure with RMSD values as low as
2.3 A˚ (Fig. 3C, Supplemental Fig. 1). This finding strongly indicates
that the crystal contacts in the BCAP TIG2a crystal represent the
physiological dimerization interface, even though TIG2a is
monomeric in solution (Fig. 2A). The TIG2a dimer also shares
the helical features of the Ebf1 structure (Supplemental Fig. 1).
The Ebf1 dimer is stabilized by the three a helices C-terminal of
the TIG domain (22, 24). This supports our SEC-MALS exper-
iments that identify a similar role for the C-terminal helices of
the DBB domain.
Although specific binding is mediated by N-terminal Rel ho-
mology domains, NF-kB, NFAT, and Ebf1 TIG domains make
sequence-unspecific contacts with the DNA phosphate backbone
through several arginine and lysine residues at the N-terminal
loops of the TIG domain (21–23). BCAP conserves these resi-
dues (arginine 205 and lysine 201, Supplemental Fig. 1C). To
investigate whether the BCAP DBB domain interacts with DNA,
the cellular localization of BCAP in human immune cells was
assessed. In chicken B cells, BCAP has been described as a cy-
tosolic protein, whereas other reports show a nuclear localization
of BCAP in HEK293 and U-2 cells (25, 26). Immunofluorescence
localization of BCAP in human THP-1 macrophages and Ramos
B cells shows an exclusively cytosolic localization (Supplemental
Fig. 2). To further evaluate potential DNA-binding ability by the
BCAP TIG fold, DNA cellulose pulldown and gel-shift assays
were conducted (Fig. 4). Whereas HMGB1 bound readily to DNA
cellulose (Fig. 4A), DBB-ANK, full-length BCAP, and the BCAP
adaptor protein CRKL (CRK-like protooncogene, adaptor protein)
did not bind (Fig. 4B–D). Similarly, whereas HMGB1 bound to a
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FIGURE 1. The BCAP DBB domain is required for negative regulation of TLR signaling. (A) HEK293T cells were transiently transfected with
FLAG-TIR, FLAG-TIR-TIG2a, FLAG-TIR-DBB, FLAG-TIR-DBB-ANK, FLAG-MyD88, and Myc-MAL. At 24 h posttransfection, cells were lysed
and subjected to immunoprecipitation with anti-FLAG Ab. Precipitates were split and assayed for the presence of FLAG-tagged BCAP constructs or
coprecipitation of Myc-tagged MAL. (B) As in (A), cells transfected with Myc-MyD88. (C) NF-kB reporter assay in HEK293T cells transiently
transfected with MAL and BCAP constructs containing various domain boundaries. The results are presented as means 6 SD (Figure legend continues)
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DNA oligonucleotide in a band shift assay, the other three proteins
did not interact (Fig. 4E).
A structural model of the BANK1 DBB domain reveals striking
similarities with the BCAP DBB domain. The paralogues BCAP
and BANK1 exhibit analogous domain architectures, with an
N-terminal TIR domain followed by a DBB domain and ankyrin
repeat followed by a C-terminal unstructured region. Moreover,
because of the high level of sequence similarity between the DBB
domains (Supplemental Fig. 3), we hypothesized that they would
adopt a similar fold including dimerization properties. To test this
hypothesis, an alignment-based model of the BANK1 DBB do-
main was obtained via the Robetta protein structure prediction
server (27). The resulting models of the BANK1 DBB domain
predict a dimeric TIG fold (Supplemental Fig. 3). The dimeriza-
tion interface is composed of the ABED b-sheet, as seen in the
experimental BCAP DBB domain structure. The RMSD values of
the BANK1 and BCAP DBB domains are as low as 1.65 A˚. This
level of structural similarity is unexpected because the BANK1
DBB domain model was obtained independently of the BCAP
DBB domain structure. Furthermore, the BCAP DBB domain
structure presented in this study was obtained using experimental
phases and thus not biased by existing TIG structures in the PDB.
These DBB domain similarities once again support the concept of
DBB domain dimerization via the ABED b-sheet and suggest a
high level of functional conservation, including regulation of TIR
domain interactions.
Discussion
In this study, we provide the first direct evidence, to our knowledge,
that the BCAP TIR domain forms heterotypic interactions with the
MAL adaptor protein. The BCAP TIR domain is monomeric in
solution (13) and may assemble with oligomers of MAL and
MyD88 TIR domains during signal transduction. With regard to
negative regulation of TLR signaling, we show that the BCAP
TIR domain requires indirect dimerization via its DBB domain to
inhibit TLR signaling in NF-kB reporter assays. We also find that
the BCAP TIR alone enhances signaling by MyD88 and MAL
possibly because the monomeric BCAP TIR destabilizes auto-
inhibited MyD88, triggering Myddosome assembly (28). Although
stable dimers of animal TIR domains have not been demonstrated,
this form of indirect dimerization through an adjacent domain is seen
with SARM, another negative regulator of the TLR pathways (29).
Our findings also indicate that dimeric BCAP disrupts the for-
mation of MAL filaments in vitro, perhaps by enhancing filament
based on quintuple samples from one of three independent experiments. Statistical significance was analyzed by using a two-tailed ANOVA test, in which
p , 0.05 was deemed significant. (D) As in (C), cells transfected with MyD88. (E) HEK293T cells were transiently transfected with Myc-MAL,
Myc-MyD88, and BCAP constructs containing various domain boundaries, as indicated. After lysis, samples were analyzed for NF-kB reporter activity and
probed for the expression of Myc-MAL and Myc-MyD88 by Western blot. Myc-TIR-DBB is also detected in these experiments as it has a similar Mr to
MAL and MyD88 (extra band in lanes 4 and 11). (F) Schematic depiction of domain boundaries for constructs used in this study.
FIGURE 2. BCAP disrupts MAL filament formation through DBB domain dimerization. (A) SEC-MALS analysis of the DBB-ANK (residues 179–404,
monomer Mr = 24.5 kDa), TIG2a (residues 179–288, monomer Mr = 12.4 kDa), and TIR-DBB (residues 7–330, monomer Mr = 35.5 kDa). (B) To assess
filament formation, MAL TIR domain was incubated at 30˚C for 1 h either alone or in the presence of BCAP constructs, as indicated. Soluble supernatant
(SN) and pellet fraction (P) were then separated by differential centrifugation and analyzed by SDS-PAGE, stained with Coomassie blue dye (seeMaterials
and Methods). (C) Analytical size exclusion chromatography of purified, unpolymerized MALTIR domain and BCAP(FL) after incubation at 30˚C for 1 h.
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nucleation. This suggests that the physiological inhibition of
TLR signaling by BCAP is in part driven by a steric inhibition of
the TIR signalosome in addition to phosphoinositide meta-
bolism and the regulation of the FoxO1 TF (10, 12, 14). Al-
though these models address the observed regulation of surface
TLRs, BCAP can also inhibit signaling by endosomal TLRs
(10, 11). In endosomal membranes, all PIP lipids are phos-
phorylated at the three position, and thus it is unlikely that
PI3K plays a role. Thus, steric inhibition of the TLR signal-
osomes by BCAP may be a primary mechanism for these TLRs.
BCAP also functions in the IL-1 (IL-1R) and IL-18R pathways
in CD4+ T cells. Interaction of BCAP with the TIRs of these
receptors activates the PI3K–mTOR pathway and enhances
Th17 and Th1 cell responses (30).
At a structural level, similarities between the DBB domain TIG
fold and NF-kB family TF revealed the physiological dimerization
site of BCAP and illustrated the importance of the C-terminal
DBB a helices. The BCAP TIG fold is especially similar to
Ebf-1 because both structures conserve a three a helix motif at the
C-terminal that is required to form a stable dimer. This helix-loop-
helix is not present in other family TFs and is not required for
dimerization that occurs between the ABED b-strands of the Ig
fold. We also show that the BCAP does not bind DNA or localize
to the nucleus. Thus, BCAP TIG is the first example, to our
knowledge, of this dimerization module being appropriated by
cytosolic signaling regulators.
The structural and functional characterization of the BCAP DBB
domain has strong implications for its homolog BANK1. BANK1 is
required for the production of various proinflammatory cytokines
and has been associated with systemic lupus erythematosus (SLE),
systemic sclerosis, and rheumatoid arthritis in multipole genome-
wide association studies (31–34). On a molecular level, BANK1
was associated with TLR7 and TLR9 signaling in B cells (35, 36).
Our model of the BANK1 DBB domain revealed that BANK1
shares a high level of sequence similarity and structure with the
BCAP DBB domain. Moreover, because BANK1 was recently
shown to contain a functional TIR domain, we propose that
BANK1 TIR domain interactions are regulated by DBB domain
FIGURE 3. The BCAP DBB domain structure reveals striking similarities to TF TIG domains. (A) The structure is composed of a core TIG fold,
followed by two C-terminal a helices. (B) Structural alignment of the DBB TIG fold (green) and TIG domains from various TF. Ebf1 (teal, PBD 3MLP),
CAMTA1 (purple, PDB 2CXK), NFAT5 (gray, PDB 1IMH), and p50 NF-kB dimer (yellow, PDB1NFK). (C) Structural alignment of known TIG dimers
from (A) with the BCAP DBB domain interface 1 putative dimer. The DBB domain TIG2a structure is shown (in green) with Ebf1 (teal), CAMTA1
(purple), NFAT5 (gray), and p50 NF-kB dimer (yellow).
Table I. Overview of structural similarities between BCAP DBB and TF TIG domains
TF PDB Code BCAP Sequence Identity (%) Monomer RMSD (A˚) Dimer RMSD (A˚) Dimer Interface (A˚2)
NFAT5 (dimer) 1IMH 13.2 2.2 2.3 596
NFAT1 1A02 8.6 2.1
p50 NF-kB (dimer) 1NFK 13.4 2.4 3.3 683
Ebf1 (dimer) 3MLP 14.8 2.8 3.6 463
CAMTA1 (putative dimer) 2CXK 12.8 1.6 2.2 598
2274 DIMERIZATION OF B CELL ADAPTOR PROTEIN
dimerization. Similar to the MyD88–BCAP complex, the BANK1
DBB domain is likely required for TIR domain interactions with
MyD88 as well as subsequent signaling. BANK1 DBB domain
dimerization also provides a mechanism of regulating the relative
activity of BANK1 isoforms with and without the TIR domain. It
was recently shown that the strength of TIR domain interactions
between BANK1 and MyD88 is linked to several autoimmune
phenotypes, including SLE (37). DBB domain dimerization likely
regulates this TIR domain activity through the formation of
BANK1 heterodimers composed of the full-length protein and
isoform lacking the TIR domain (BANK1-D2). This hypothesis is
supported by the observation that some SLE-associated SNPs
result in altered ratios of full-length and BANK1-D2 (33, 38).
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